W hen patients with depression begin antidepressant therapy, sometimes a benzodiazepine is added to the therapy to mitigate the anxiety and insomnia that occur with depression, 1,2 reduce depression severity more quickly, 2, 3 and improve antidepressant persistence. 2 Because benzodiazepine dependency may develop quickly, 4-6 practice guidelines recommend only short-term benzodiazepine use. 7 For example, the United Kingdom National Institute for
Health and Care Excellence depression guideline cautions against using a benzodiazepine for more than 2 weeks when prescribed to patients also taking antidepressants, noting further that it remains unclear whether starting benzodiazepine therapy at antidepressant therapy initiation produces desirable effects in efficacy or tolerability. 8 Despite cautions and concerns, benzodiazepines are commonly prescribed during antidepressant treatment; 10% to 57% of antidepressant users receive benzodiazepines or other anxiolytics at some time during antidepressant treatment. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Less is known about the specific practice of simultaneously beginning benzodiazepine therapy with antidepressant therapy. The largest US study 19 used Veterans Health Administration data and found that 7.6% of adults with depression who initiated antidepressant treatment in 2007 also initiated benzodiazepine treatment on the same day; 14.1% continued benzodiazepine treatment for 1 year. Patients who simultaneously started use of these drugs were more likely to have anxiety and to visit a psychiatrist.
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Comparable statistics for privately insured adults in the United States, who comprise 64% of all US adults aged 18 to 64 years in 2012, 20 have not been published, to our knowledge.
To address current research gaps in US commercially insured adults, we describe (1) how frequently antidepressant initiators simultaneously start benzodiazepine therapy, (2) changes in simultaneous new use over time, and (3) the proportion of simultaneous new users who become long-term benzodiazepine users. In addition, we assessed whether antidepressant treatment length varies between simultaneous new users and non-simultaneous new users and identify determinants of simultaneous new use and long-term benzodiazepine use.
Methods

Data Source and Study Population
We used Truven's MarketScan Commercial Claims and Encounters Database. The database includes claims for inpatient and outpatient diagnoses, procedure codes, and records for reimbursed, dispensed prescriptions for privately insured individuals. The study population consisted of adults aged 18 to 64 years with a recent depression diagnosis who initiated antidepressant treatment from January 1, 2001, through December 31, 2014. Included adults had no record of a benzodiazepine or antidepressant prescription in the year before antidepressant treatment initiation. All antidepressant types were included (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, tricyclic antidepressants, and others 
Simultaneous New Use
Simultaneous new use was defined as a record of a dispensed benzodiazepine prescription on the date of antidepressant treatment initiation. All patients were previously naive to treatment with antidepressants and benzodiazepines. Sensitivity analyses defined simultaneous new use as a benzodiazepine dispensed up to 30 days after antidepressant treatment initiation.
Antidepressant Treatment Length
Antidepressant treatment length was defined as the number of days from antidepressant treatment initiation to discontinuation. After the date of antidepressant treatment initiation, the days' supply was added to a 30-day grace period to
Key Points
Questions When adults with depression begin antidepressant therapy, how often do they simultaneously begin benzodiazepine therapy, does antidepressant treatment length differ in patients with simultaneous new use of an antidepressant and benzodiazepine, and how often does beginning use of the medications together result in long-term benzodiazepine use?
Finding In this cohort study of 765 130 adults who started taking an antidepressant, 81 020 also started taking a benzodiazepine the same day, with the proportion of patients with simultaneous new antidepressant and benzodiazepine use increasing from 6.1% in 2001 to 12.5% in 2012 (then plateauing through 2014). No clinically meaningful difference in antidepressant treatment continuation by simultaneous antidepressant and benzodiazepine new use was found, and 12.3% of patients who began treatment with both these agents had long-term (6-month) benzodiazepine use.
Meaning The decision to prescribe a benzodiazepine when a patient begins antidepressant therapy requires careful consideration of potential benefits and harms.
allow for gaps in treatment between fills. If no subsequent prescription was dispensed in the previous prescription's days' supply plus the grace period, the patient was considered to have discontinued treatment at the end of that period. We highlight antidepressant treatment continuation at 6 months because guidelines recommend 6 or more months of treatment in adults with depression 1 but also report results up to 2 years.
Long-term Use of Benzodiazepine
Applying a commonly used definition, 21 we defined longterm benzodiazepine use as 6 months (180 days) of continuous benzodiazepine use after simultaneous new use with antidepressant treatment. We estimated benzodiazepine treatment length using a 30-day grace period; sensitivity analyses varied the grace period from a more restrictive (10 days) to a less restrictive definition (60 days). We also counted the number of benzodiazepine prescription fills before discontinuation of use.
Patient and Prescribing Characteristics
Patient and prescribing characteristics were based on the presence of diagnostic and procedure codes and dispensed prescriptions in the year before antidepressant initiation. These characteristics included age, sex, psychiatric comorbidities (specific consideration to anxiety disorders), treated selfharm, nonpsychiatric comorbidities (included individually and not part of an index), health care use (often used as a proxy for health-seeking behavior and overall health), and region. We also included year of antidepressant treatment initiation, initial antidepressant class, and a marker for recorded psychotherapy sessions (Current Procedural Terminology psychotherapy codes) in the 30 days before antidepressant treatment initiation. Although we lack direct measures of baseline depression severity, for the index depression diagnosis we included the specific depression diagnosis, whether the index episode was diagnosed in the hospital or as an outpatient, and the physician specialty associated with the diagnosis. Because benzodiazepines have been associated with fractures 22, 23 and the potential harms of concurrent benzodiazepine and opioid use, 24-26 we included indicators for recent opioid prescriptions, prior injuries, and fall or fracture risk factors. We characterized the initial benzodiazepine prescription in terms of days' supply and quantity of pills dispensed, pills per day prescribed (quantity divided by days' supply), whether the agent was long-acting (clonazepam, clorazepate, diazepam, flurazepam, or quazepam), 27 and whether the dose per day (prescription strength × pills per day) was above, below, or at the modal dose. Modal dose per day was determined by the mode dose for each benzodiazepine agent. For patients with more than 1 benzodiazepine agent (0.9%) dispensed at treatment initiation or more than 1 prescription for the same agent (0.5%), we summed initial days' supply, quantity, and pills per day values.
Statistical Analysis
We estimated the proportion of simultaneous antidepressant and benzodiazepine users among all antidepressant initiators by year, stratified by age group and physician type. We estimated the mean annual increase and 95% CIs in the propor- 
Trends in Simultaneous New Use
The proportion of simultaneous new users increased from 6.1% 
Determinants of Benzodiazepine and Antidepressant Simultaneous New Use
Having a recent anxiety diagnosis was the strongest determinant of simultaneous new use of a benzodiazepine ( 
Antidepressant Treatment Length
A total of 67.3% of simultaneous new users and 70.3% of nonsimultaneous new users continued antidepressant treatment at 3 months; 44.3% of simultaneous new users and 47.1% of non-simultaneous new users continued to take antidepressants at 6 months. After propensity score weighting, crude imbalances between simultaneous new users and nonsimultaneous new users were mitigated, but results at 6 months were unchanged (non-simultaneous new users, 47.1%; simultaneous new users, 43.9%) ( Figure 2) . Continued antidepressant use at 6 months was similar in the subset of adults with major depressive disorder (n = 201 969; non-simultaneous new users, 48.1%; simultaneous new users, 45.6%).
Benzodiazepine Prescription Details
Most benzodiazepine users had an initial prescription for alprazolam (43.9%), lorazepam (26.3%), or clonazepam (21.8%). A total of 13.5% received a short benzodiazepine days' supply (1-7 days) at the start of treatment, with variation by physician specialty (psychiatry, 6.7%; family practice, 15.1%). A total of 26.1% of simultaneous new users received more than 50 benzodiazepine pills at the start of treatment, an indication of prescribing more than 1 pill per day. We present full benzodiazepine prescription details overall and by physician in eTable 2intheSupplement.
Long-term Benzodiazepine Use
A total of 12.3% (95% CI, 12.0%-12.5%) of simultaneous new users received long-term benzodiazepine treatment, with 5.7% (95% CI, 5.5%-5.9%) continuing benzodiazepine therapy for 1 year. Of simultaneous new users, 6.2% under the shortened (10 days) and 22.0% under the lengthened (60 days) grace periods were defined as long-term users. The proportion of simultaneous new users becoming long-term users remained fairly stable from 2001 to 2014 (eFigure 2 in the Supplement). Among simultaneous new users with 6 months or more of insurance enrollment after the start of treatment (61 482 [75.9%]), 64.0% did not refill their initial benzodiazepine prescription, and 14.8% had 4 or more refills before treatment discontinuation ( Table 2) .
When simultaneously considering long-term benzodiazepine use and antidepressant treatment continuation in adults with 6-month follow-up, 34.9% continued antidepressant treatment and discontinued benzodiazepine treatment 6 months after the start of treatment, 8.3% continued both antidepressant and benzodiazepine treatment, 54.4% discontinued both antidepressant and benzodiazepine treatment, and 2.4% continued benzodiazepine treatment and discontinued antidepressant treatment.
The likelihood of becoming a long-term benzodiazepine user varied by patient and prescription characteristics (Table 3 and eTable 3 in the Supplement). Patients with an initial days' supply of 8 to 15 days (RR, 1.46; 95% CI, 1.30-1.64), 22 to 35 days (RR, 2.91; 95% CI, 2.54-3.33), and more than 35 days (RR, 4.90; 95% CI, 4.15-5.79; prevalence, 2%) were more likely to become long-term users than were patients with 1 to 7 days' supply. Older adults (50-64 vs 18-24 years of age; RR, 1.27; 95% CI, 1.17-1.38), patients initiating a long-acting benzodiazepine (RR, 1.28; 95% CI, 1.22-1.34), and patients diagnosed with depression by a psychiatrist vs family practitioner (RR, 1.37; 95% CI, 1.27-1.47) were more likely to become long-term users. Prior poisoning (RR, 1.29; 95% CI, 1.01-1.64) and a recent opioid prescription (RR, 1.50; 95% CI, 1.39-1.61) at baseline were also associated with an increased likelihood of becoming a longterm user.
Discussion
A total of 10.6% of commercially insured adults who started taking an antidepressant after a depression diagnosis simultaneously initiated benzodiazepine therapy, increasing from 6.1% in 2001 and peaking at 12.5% in 2012. We observed no clinically meaningful difference in antidepressant treatment length between simultaneous new users and nonsimultaneous new users. Overall, 12.3% of simultaneous new users became long-term benzodiazepine users, an outcome Internally standardized (reference year, 2012) by age group, sex, and region; patients with unknown region and physician specialty were excluded (remaining n = 687 170).
more common among patients with an initial prescription for a longer benzodiazepine days' supply or long-acting benzodiazepine and recent prescription opioid fills.
Our prevalence estimates for simultaneous new use are similar to those reported in the other US population-based study 19 that examines this question in a cohort of veterans Although the trends from 2001 to 2014 were observed across all physician types, adults diagnosed with depression by a psychiatrist were more likely to simultaneously begin new use of an antidepressant and a benzodiazepine than were adults diagnosed by other physicians. The difference between physician type might be related to psychiatrists' increased familiarity with benzodiazepines, treatment preferences, and training; the severity of their patient's depression or comorbid anxiety; or the possibility that patients diagnosed by psychologists are more likely to receive prescriptions from another physician because of prescribing restrictions. On the basis of proxies for depression severity available in our data, simultaneous new use may well be more common for patients with more severe depression. Because we lack direct depression severity measures, this remains speculative. which 20% to 33% of all long-term benzodiazepine users received at least 1 benzodiazepine prescription from a psychiatrist. More emphasis on short-term use may be needed for some patients, including patients treated by non-mental health specialists. In our study, strong determinants of long-term benzodiazepine use included potentially modifiable characteristics of For adjusted analyses, we used stabilized-inverse probability of treatment weights. Variables entered into the propensity score model (collected in the year before antidepressant initiation) include sex, age, antidepressant type, specific depression diagnosis, inpatient depression diagnosis, physician type, treated self-harm event, psychotherapy use, psychiatric comorbidities with markers for anxiety disorders, and markers of health care use (outpatient visits and medication count). In the unweighted cohort, 24.1% of simultaneous new users and 22.5% of non-simultaneous new users had less than 6 months of insurance enrollment after antidepressant initiation. a Grace period indicates the number of days without medication between fills that is allowed before a patient was known to have discontinued benzodiazepine therapy.
b Restricted to simultaneous new users with 6 months of follow-up (n = 61 482). the initial regimen (eg, days' supply of the initial benzodiazepine prescription and use of long-acting agents). Future studies should focus on better understanding how days' supply and long-acting agents contribute to prolonged benzodiazepine use. Although we did not look at whether opioid use was continued after simultaneous antidepressant and benzodiazepine new use, the association between a recent baseline opioid prescription and long-term benzodiazepine use is particularly concerning because of the known risks of concurrent use of these substances and their pharmacologic interactions.
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Limitations Some limitations should be considered. Our estimates are based on dispensed prescriptions, and we cannot account for patients who were prescribed but did not fill the benzodiazepine prescription and patients who did not actually take the dispensed medications. However, irrespective of whether the medication was taken, our results focus on the clinically relevant questions surrounding coprescribing. We used the most restrictive definition of simultaneous new use in primary analyses (prescriptions filled on the same day) and, therefore, may have underestimated clinically relevant simultaneous new use. However, trends and determinants were consistent under the more liberal definition. We restricted our study to patients who started antidepressant treatment, but some could have been treated with antidepressants in the more remote past; it is possible that prior treatment experiences not captured influenced simultaneous new use decisions. Additional unknown details surrounding benzodiazepine prescriptions include whether they were prescribed as needed and how many refills were allowed. Parameter estimates from our multivariable models of simultaneous new use and long-term benzodiazepine use should not be interpreted causally. 42 In addition, our observation of no meaningful difference in antidepressant treatment length by simultaneous new use could be attributable to unmeasured confounding (eg, depression severity), misclassification, or chance.
Because we required at least a year of continuous coverage in the same health insurance plan, we could have induced a selection bias. It is possible, albeit unlikely, that those who did not meet these requirements differ in their benzodiazepine use patterns from those who we studied. Other factors that influence the generalizability include our decision to exclude patients with recorded baseline substance abuse and select psychiatric comorbidities. In addition, trends present in our data could be influenced by the underlying insurance plans that contribute to MarketScan, which varied from 2001 to 2014. Last, we cannot be certain that the antidepressant treatment was initiated for depression because of the many indications for antidepressants 43 or that the antidepressant prescriber also prescribed the benzodiazepine. However, although MarketScan data cannot identify the physician associated with dispensed prescriptions, preliminary results in a validation study reveal that the physician who diagnosed the index depression is a good proxy for the physician of the initial antidepressant prescription and that most simultaneous new users received both prescriptions from the same physician (G.A.B., unpublished data, May 1, 2017).
Conclusions
Between 
